Furthermore our results have been confirmed in subsequent independent studies; for example, TES expression was downregulated in B-lineage ALL [14, 15]; and TES promoter methylation was demonstrated to be specific to ALL in a methylation microarray study of haematological neoplasms [16]. This evidence concerns the gene TES and hematopoietic and lymphoid cell neoplasm.